What's hot with anti-aging science. 

Telocyte’s 2023 preclinical trials juiced human cell lines with telomerase activators—senescence markers tanked, cells kept trucking.

Mice are hitting 40–50% longer lives, and get this: fewer tumors. Cancer’s shaking, not just stalling. And 2024? Pig skin cells got a youth shot—smooth hides, no sag. 

CRISPR’s another beast. In 2018, it was a glimmer—by 2021, it cured sickle cell in humans, FDA-stamped in 2023. For aging, 2024’s mouse trials used CRISPR-Cas9 to zap senescent cells—liver and heart function spiked 20%¹ . 

Altos Labs, $3 billion deep since 2021, is tweaking sirtuins and NAD in humans now—David Sinclair’s rewind-the-clock hunch is in play. Trials are humming—Kids might not just live longer; they’ll live *sharp*.

Stem cells? Japan’s 2022 iPSC trials fixed blind eyes—60% see better by 2024. Anti aging’s rolling: UCLA’s 2023 stem shots cut inflammation 30% in over-60s—muscles flex, brains snap. 

Then there’s NAD—Sinclair’s babies, NR and NMN, hit the shelves big by 2020. 2024 trials show a 15% mitochondrial boost in 50 somethings—energy’s up, fatigue’s down  Senolytics, those junk-cell cleaners, are in too.

Mayo Clinic’s 2023 human tests cut frailty 25% in 65+ folks. 

Funding’s still the hitch—FDA’s billion-dollar gauntlet slows it, but private cash (Altos, Calico) and public donors are the current jet fuel.

*** Taken from the newest edition of
Living Toward Everything

Scroll Down to Get a Free E-Book version.